News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. is pleased to announce its achievement of a score of 44 out of 100 in the 2024 S&P Global Corporate Sustainability Assessment. This marks an improvement of 6 points compared to the previous assessment, with advancements observed across all three dimensions. (CSA Score as of November 27, 2024).
In the latest assessment, Porton’s scores increased by 3 points in the Environmental dimension, 5 points in the Social dimension, and 9 points in the Governance & Economic dimension. Significant progress was noted in areas such as Transparency and Reporting, Materiality, Climate Strategy, Labor Practices, Human Rights, and Supply Chain Management.
Guided by the ESG principles of "Green Development, Promoting Common Progress, Building a Healthy Society, and Enhancing Corporate Governance," Porton is dedicated to embedding ESG values into its corporate strategy and operations. In 2024, Porton further strengthened its ESG management by implementing various initiatives, including developing management systems, setting targets, and enhancing the quality of disclosures. Moving forward, Porton remains committed to practicing ESG principles and fostering sustainable development.
Others
MoreNews 2025-01-14
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
News 2024-12-23
Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership
On December 20, 2024, Porton Pharma Solutions Ltd. (hereinafter referred to as “Porton Pharma Solutions” or “Porton”) and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as “Dragon Sail Pharmaceutical”) formally signed a strategic cooperation agreement in Guilin, southern of China.